+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Giant Cell Arteritis Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767437
  • Report
  • April 2019
  • Region: Global
  • 71 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Napp Pharmaceuticals Ltd
  • MORE
The global clinical trial report- “2019 Giant Cell Arteritis Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Giant Cell Arteritis. It presents in-depth analysis of Giant Cell Arteritis clinical trials across markets and companies. The research work is for providing complete understanding into trends in Giant Cell Arteritis.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Giant Cell Arteritis clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Giant Cell Arteritis

The research work is prepared through extensive and continuous research on Giant Cell Arteritis trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Giant Cell Arteritis patients are identified
  • The report includes panorama of Giant Cell Arteritis clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Giant Cell Arteritis clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Napp Pharmaceuticals Ltd
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Giant Cell Arteritis Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Giant Cell Arteritis Clinical Trials by Region
2.2.2 Average Enrollment of Giant Cell Arteritis Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Giant Cell Arteritis Treatment, 2019

3. Region wise Giant Cell Arteritis Clinical Trials
3.1 Asia Pacific Giant Cell Arteritis Clinical Trials by Country
3.2 Europe Giant Cell Arteritis Clinical Trials by Country
3.3 North America Giant Cell Arteritis Clinical Trials by Country
3.4 Middle East and Africa Giant Cell Arteritis Clinical Trials by Country
3.5 South and Central America Giant Cell Arteritis Clinical Trials by Country

4. Giant Cell Arteritis Clinical Trial Trends
4.1 Start Year wise Giant Cell Arteritis Clinical Trials
4.2 Phase wise Giant Cell Arteritis Clinical Trials
4.3 Trial Status wise Giant Cell Arteritis Clinical Trials
4.4 Trial Type wise Giant Cell Arteritis Clinical Trials

5. Giant Cell Arteritis Average Enrollment Trends
5.1 Average Enrollment in Giant Cell Arteritis Trials by Year
5.2 Average Enrollment in Giant Cell Arteritis Trials by Phase
5.3 Average Enrollment in Giant Cell Arteritis Trials by Status
5.4 Average Enrollment in Giant Cell Arteritis Trials by Type of Trial

6. Companies Participating in Giant Cell Arteritis Clinical Trials
6.1 Giant Cell Arteritis Trials by Sponsor Type
6.2 Giant Cell Arteritis Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Giant Cell Arteritis Trials- Phase 1
7.2 Giant Cell Arteritis Trials- Phase 2
7.3 Giant Cell Arteritis Trials- Phase 3
7.4 Giant Cell Arteritis Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Giant Cell Arteritis Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Giant Cell Arteritis Clinical Trials and Enrolment
Figure 5: Europe - Country wise Giant Cell Arteritis Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Giant Cell Arteritis Clinical Trials and Enrolment
Figure 7: North America - Country wise Giant Cell Arteritis Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Giant Cell Arteritis Clinical Trials and Enrolment
Figure 9: Giant Cell Arteritis Clinical Trials by Phase
Figure 10: Giant Cell Arteritis Clinical Trials by Trial Status
Figure 11: Giant Cell Arteritis Clinical Trials by Type
Figure 12: Giant Cell Arteritis Clinical Trials by Sponsor Type
Figure 13: Giant Cell Arteritis Clinical Trials by Leading Sponsors
Figure 14: Giant Cell Arteritis Average Enrollment by Phase
Figure 15: Giant Cell Arteritis Average Enrollment by Trial Status
Figure 16: Giant Cell Arteritis Average Enrollment by Type
Figure 17: Giant Cell Arteritis- Average Enrolment by Type of Sponsors
Figure 18: Giant Cell Arteritis- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Giant Cell Arteritis Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Giant Cell Arteritis Clinical Trials and Enrolment
Table 5: Europe - Country wise Giant Cell Arteritis Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Giant Cell Arteritis Clinical Trials and Enrolment
Table 7: North America - Country wise Giant Cell Arteritis Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Giant Cell Arteritis Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Giant Cell Arteritis Average Enrollment by Phase
Table 15: Giant Cell Arteritis Average Enrollment by Trial Status
Table 16: Giant Cell Arteritis Average Enrollment by Type
Table 17: Giant Cell Arteritis- Average Enrolment by Type of Sponsors
Table 18: Giant Cell Arteritis- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie Inc
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Les Laboratoires Servier SAS
  • Napp Pharmaceuticals Ltd
Note: Product cover images may vary from those shown
Adroll
adroll